Date: 2017-05-23
Type of information: Product acquisition
Compound: IMGN529/DEBIO 1562
Company: Immunogen (USA - MA) Debiopharm (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: product acquisition
Action mechanism: antibody drug conjugate. IMGN529 is a CD37-targeting antibody drug conjugate (ADC) created by ImmunoGen for the treatment of B-cell malignancies. It consists of a CD37-binding antibody with one of the Company's potent cancer cell-killing agents, DM1, attached. The antibody serves to deliver the DM1 specifically to B cells to kill them and, based on preclinical research, also contributes anticancer activity.
Disease: B-cell malignancies, such as non-Hodgkin lymphomas
Details:
- • On May 23, 2017, Debiopharm, a Switzerland-based biopharmaceutical company, and ImmunoGen, a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced that Debiopharm has acquired ImmunoGen's IMGN529/DEBIO 1562, a clinical-stage anti-CD37 ADC for the treatment of patients with B-cell malignancies, such as non-Hodgkin lymphomas (NHL).
- IMGN529/DEBIO 1562 demonstrated evidence of anticancer activity in NHL in a Phase 1 monotherapy trial and successfully completed a safety run-in study in combination with Rituxan®. The product is now ready to move forward into a Phase 2 trial in NHL, and particularly in DLBCL for which it has orphan drug status.
Financial terms:
- Under the terms of the agreement, ImmunoGen received a $25 million upfront payment for IMGN529/DEBIO 1562 and is entitled to a $5 million milestone payment to be paid after completion of the transfer of ImmunoGen technologies related to the asset, which the parties expect to achieve by the end of 2017. In addition, ImmunoGen is eligible for a second success-based milestone payment of $25 million upon IMGN529/DEBIO 1562 entering a Phase 3 clinical trial.
Latest news:
Is general: Yes
